Reinforcing the objective of establishing a link between laboratory research and application in patient care, by means of the development and use of innovative technology, BraIns produces the radiopharmaceutical [18F]Flumazenil, which assists the tracing of the epileptogenic focus, so it is an important part in the evaluation of patients with epilepsies of difficult medication-based control.
Another important radiopharmaceutical, also marked with fluorine-18, is the [18F]FET, a tyrosine analogue, and a tracer of intracranial neoplasia. BraIns also produces radiopharmaceuticals marked with carbon-11, which has a half-life of just 20 minutes. Such a short half-life requires the radiopharmaceutical to be injected in the patient very swiftly after it is produced. This is possible due to the excellent infrastructure available at BraIns, made up of the Radiopharmaceutical Production Center and the Molecular Imaging Center, which has a PET/CT device, used for the images of the examinations performed.
Alzheimer’s disease, a neurodegenerative process that affects a portion of the population, is characterized by the formation and accumulation of plaques and filaments of structures called beta amyloids in certain regions of the brain. Clinical and pathological evidence suggests that such deposits begin decades before the signs of dementia. Thus, if the presence of beta amyloid plaques in patients is detected early, it may be possible to alleviate or prevent the progress of Alzheimer’s disease.
The radiopharmaceutical [11C]PIB, Pittsburgh Compound B will be used to detect those beta amyloid plaques. It is considered gold standard in detecting that kind of plaques.